MARKET

DVAX

DVAX

Dynavax Techs
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.320
-0.210
-4.64%
After Hours: 4.410 +0.09 +2.08% 19:59 09/24 EDT
OPEN
4.500
PREV CLOSE
4.530
HIGH
4.500
LOW
4.220
VOLUME
3.90M
TURNOVER
--
52 WEEK HIGH
12.44
52 WEEK LOW
1.800
MARKET CAP
473.09M
P/E (TTM)
-2.6936
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Dynavax CFO Michael Ostrach announces planned retirement in 2021
Dynavax Technologies (DVAX) SVP, CFO and CBO Michael Ostrach announced his planned retirement in 2021.As part of the planned transition next year, the company has retained Russell Reynolds Associates to assist the Company
Seekingalpha · 10h ago
Dynavax Announces Appointment of New Board Member and Planned Retirement of Chief Financial Officer
Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Peter R. Paradiso, Ph.D. to its Board of Directors. Separately, the Company also announced that Michael Ostrach, Senior Vice President
PR Newswire · 11h ago
All six COVID-19 vaccines in industrial manufacturing - HHS Secretary Azar
Bloomberg reports that, according to Health and Human Services ((HHS)) Secretary Alex Azar, all six frontrunning COVID-19 vaccines are being produced at industrial scale.The companies have all previously announced production
Seekingalpha · 17h ago
White House may overrule tightening of FDA vaccine rules
Reports on Tuesday suggested the FDA was considering stricter guidelines for emergency-use authorization of a coronavirus vaccine, though the White House may not approve of it."It sounds like a political
Seekingalpha · 23h ago
Fintech Focus For September 24, 2020
Benzinga · 1d ago
Stricter FDA standards make COVID-19 vaccine approval unlikely before election day
The Washington Post reports that tougher FDA standards for emergency use authorization ((EUA)) of a COVID-19 vaccine will extend the review timeline and make it unlikely that a nod could
Seekingalpha · 2d ago
Global vaccine plan gains momentum, U.S. not on board
An $18B initiative to ensure any future vaccine against COVID-19 is fairly shared throughout the world has secured the backing of 156 countries and territories, representing about 64% of the
Seekingalpha · 2d ago
Valneva and Dynavax Announced Commercial Supply Agreement for Inactivated, Adjuvanted COVID-19 Vaccine; Dynavax to Provide CpG 1018 to Produce up to 190M Doses over a Five-Year Period
Valneva SE ("Valneva"), a specialty vaccine company focused on prevention of diseases with major unmet needs, and Dynavax Technologies Corporation (Nasdaq: DVAX) today announced a commercial partnership for the supply of Dynavax's CpG 1018 adjuvant for use in Valneva's SARS-CoV-2 vaccine candidate, VLA2001.
Benzinga · 09/14 09:58
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DVAX. Analyze the recent business situations of Dynavax Techs through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DVAX stock price target is 15.33 with a high estimate of 20.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 209
Institutional Holdings: 97.40M
% Owned: 88.94%
Shares Outstanding: 109.51M
TypeInstitutionsShares
Increased
51
13.10M
New
62
8.21M
Decreased
25
6.23M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.88%
Pharmaceuticals & Medical Research
-0.82%
Key Executives
Chairman/Independent Director
Andrew Hack
President/Chief Operating Officer
David Novack
Chief Executive Officer/Director
Ryan Spencer
Chief Financial Officer/Senior Vice President
Michael Ostrach
Senior Vice President
Robert Janssen
Chief Accounting Officer
Justin Burgess
Director
Julie Eastland
Director
Brent MacGregor
Independent Director
Francis Cano
Independent Director
Daniel Kisner
Independent Director
Arnold Oronsky
Independent Director
Peggy Phillips
Independent Director
Natale Ricciardi
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About DVAX
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Dynavax Technologies Corporation stock information, including NASDAQ:DVAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DVAX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DVAX stock methods without spending real money on the virtual paper trading platform.